bs_bs_banner

Clinical and Experimental Immunology

P O S T E R P R E S E N TAT I O N S

doi:10.1111/cei.12554

7th International Immunoglobulin Conference: Poster Presentations

K. Warnatz,* M. Ballow,† M. Stangel‡ and V. Bril§ *Centre for Chronic Immunodeficiencies, Freiburg, Germany, †University of South Florida, St Petersburg, FL, USA, ‡Department of Neurology, Hannover Medical School, Hannover, Germany, and §University of Toronto, Toronto, Canada

Correspondence: K. Warnatz. E-mail: [email protected]

162

Summary The pan-European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first-line treatment for PIDs, the mechanisms of action of Ig therapy may differ according to the condition it is used to treat. Moreover, intriguing presentations suggest that further investigation is required to understand more clearly both the haematological and immunoregulatory effects of therapeutic immunoglobulin. This can ultimately provide more information on optimizing Ig therapy efficacy, and establish whether individualized dosing regimens for patients will be conducive to better clinical outcomes. In addition to treating autoimmune and inflammatory conditions, there is evidence to suggest that immunoglobulins can potentially play a role in transplantation, which warrants further investigation for future use.

© 2014 British Society for Immunology, Clinical and Experimental Immunology, 178: 162

This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.

7th International Immunoglobulin Conference: Poster presentations.

The pan-European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy...
73KB Sizes 6 Downloads 24 Views

Recommend Documents


7th International Immunoglobulin Conference: Transplantation.
The data presented highlight the complexity of the immune response during transplantation. Early identification and characterization of donor-specific anti-HLA antibodies (DSAs) allows for identification of patients at high risk of transplant rejecti

7th International Immunoglobulin Conference: Immunodeficiencies.
Awareness of the challenges involved in diagnosing and treating a heterogeneous group of immunodeficiency disorders is growing. The improvements in neonatal screening offer new methods to ensure that primary immunodeficiencies (PIDs) are diagnosed as

7th International Immunoglobulin Conference: Immunomodulation.
Rheumatoid arthritis (RA) is a debilitating autoimmune disease that is usually treated aggressively to slow the rate of joint destruction. The therapeutic strategy used at the French centre, described here, is to use the non-biological disease-modify

7th International Immunoglobulin Conference: Immunomodulation.
Immunomodulation uses synthetic, natural and recombinant preparations to modify the immune response to a desired level, typically to treat specific autoimmune diseases, as will be discussed in this section. Rheumatoid arthritis (RA) is a common syste

7th International Immunoglobulin Conference: Transplantation.
In transplantation, harnessing the immune system is essential for allograft survival and function. This session explores different aspects of the immune system during transplantation, including the effect of donor-specific anti-human leucocyte antige

7th International Immunoglobulin Conference: Neurology.
Data presented demonstrate the versatility of immunoglobulin (Ig) therapy for a variety of neurological disorders with different pathogenesis and presentations. In indications where the efficacy of Ig is well established, the neurology community is s

7th International Immunoglobulin Conference: Neurology.
Immunoglobulin (Ig) therapy has been used and studied as a treatment for a variety of neurological conditions for decades. In some of these disorders Ig therapy has a significant role as a first-line treatment. This session explores the use of Ig the

7th International Immunoglobulin Conference: Mechanisms of action.
The mechanism of action by which therapeutic administration of intravenous immunoglobulin (IVIg) is able to provide a beneficial effect in autoimmune and inflammatory diseases is not yet fully understood, but current research is providing some answer

7th International Immunoglobulin Conference: Interlaken Leadership Awards.
The research presented in this section explores novel applications of immunoglobulin (Ig) therapy in neurological disorders. The results from the upcoming and ongoing trials of Drs Honnorat and Gamez are expected to provide meaningful insights into t